We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
Read MoreHide Full Article
Key Takeaways
{\"0\":\"AVNS acquired Nexus Medical to expand its Specialty Nutrition Systems business.\",\"1\":\"The deal adds TKO connector to AVNS\' portfolio, reducing occlusions and infection risks in IV therapy.\",\"2\":\"The acquisition is cash-funded and immediately accretive to AVNS revenues and EPS.\"}
Avanos Medical, Inc. (AVNS - Free Report) recently announced that it has acquired Nexus Medical, LLC, a privately held device maker based in Lenexa, KS, to expand its footprint in critical care for nutrition and medication delivery. The move strengthens Avanos’ Specialty Nutrition Systems business and underscores its strategy to advance safe and reliable therapy delivery in high-acuity settings.
With this acquisition, Avanos has added Nexus Medical’s proprietary TKO anti-reflux needleless connector technology, a product designed to minimize blood reflux during intravenous nutrition and medication delivery. The technology, which utilizes a patented tri-seal silicone valve, addresses a key clinical challenge by reducing catheter occlusions, therapy delays, and the risk of infection. Its adoption has been particularly strong in Neonatal and Pediatric Intensive Care Units (NICUs and PICUs), where consistency and safety in therapy delivery are paramount.
Avanos financed the acquisition with existing cash reserves. The transaction is expected to be immediately accretive to both revenue growth and earnings per share, providing a near-term boost to the company’s financial profile.
Likely Trend of AVNS Stock Following the News
In the year-to-date period, Avanos’ shares have plunged 25.5% compared with an 11% decline in the industry. The S&P 500 composite has increased 13.4% in the same time frame.
Image Source: Zacks Investment Research
The acquisition of Nexus Medical is expected to generate a favorable response from investors, given its immediate accretive impact on revenues and earnings. The deal strengthens Avanos’ positioning in critical care, a market segment with stable demand and high clinical importance, which could enhance investor confidence in the company’s growth trajectory. Shares of AVNS may see near-term upside as markets price in improved profitability and a more competitive product portfolio, though sustained momentum will depend on successful integration and execution in the Specialty Nutrition Systems segment.
Acqusition Boosts Neonatal and Pediatric Care
The addition of Nexus Medical’s product line reinforces Avanos’ emphasis on innovation tailored to neonatal and pediatric care, a niche segment where specialized devices can materially impact outcomes. With hospitals increasingly prioritizing patient safety protocols and infection prevention, the TKO connector aligns with market demand for trusted solutions that help clinicians streamline workflows while minimizing risk.
By integrating Nexus Medical’s proven technology, Avanos strengthens its competitive standing against larger medtech peers and deepens its presence in the high-value neonatal and pediatric care markets. The acquisition not only diversifies Avanos’ offerings but also supports its broader strategy of investing in innovations that meet the evolving needs of clinicians in acute care environments. This also positions Avanos to capture additional market share and broaden its critical care solutions portfolio.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, currently sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
Key Takeaways
Avanos Medical, Inc. (AVNS - Free Report) recently announced that it has acquired Nexus Medical, LLC, a privately held device maker based in Lenexa, KS, to expand its footprint in critical care for nutrition and medication delivery. The move strengthens Avanos’ Specialty Nutrition Systems business and underscores its strategy to advance safe and reliable therapy delivery in high-acuity settings.
With this acquisition, Avanos has added Nexus Medical’s proprietary TKO anti-reflux needleless connector technology, a product designed to minimize blood reflux during intravenous nutrition and medication delivery. The technology, which utilizes a patented tri-seal silicone valve, addresses a key clinical challenge by reducing catheter occlusions, therapy delays, and the risk of infection. Its adoption has been particularly strong in Neonatal and Pediatric Intensive Care Units (NICUs and PICUs), where consistency and safety in therapy delivery are paramount.
Avanos financed the acquisition with existing cash reserves. The transaction is expected to be immediately accretive to both revenue growth and earnings per share, providing a near-term boost to the company’s financial profile.
Likely Trend of AVNS Stock Following the News
In the year-to-date period, Avanos’ shares have plunged 25.5% compared with an 11% decline in the industry. The S&P 500 composite has increased 13.4% in the same time frame.
Image Source: Zacks Investment Research
The acquisition of Nexus Medical is expected to generate a favorable response from investors, given its immediate accretive impact on revenues and earnings. The deal strengthens Avanos’ positioning in critical care, a market segment with stable demand and high clinical importance, which could enhance investor confidence in the company’s growth trajectory. Shares of AVNS may see near-term upside as markets price in improved profitability and a more competitive product portfolio, though sustained momentum will depend on successful integration and execution in the Specialty Nutrition Systems segment.
Acqusition Boosts Neonatal and Pediatric Care
The addition of Nexus Medical’s product line reinforces Avanos’ emphasis on innovation tailored to neonatal and pediatric care, a niche segment where specialized devices can materially impact outcomes. With hospitals increasingly prioritizing patient safety protocols and infection prevention, the TKO connector aligns with market demand for trusted solutions that help clinicians streamline workflows while minimizing risk.
By integrating Nexus Medical’s proven technology, Avanos strengthens its competitive standing against larger medtech peers and deepens its presence in the high-value neonatal and pediatric care markets. The acquisition not only diversifies Avanos’ offerings but also supports its broader strategy of investing in innovations that meet the evolving needs of clinicians in acute care environments. This also positions Avanos to capture additional market share and broaden its critical care solutions portfolio.
AVANOS MEDICAL, INC. Price
AVANOS MEDICAL, INC. price | AVANOS MEDICAL, INC. Quote
AVNS’ Zacks Rank & Key Picks
Currently, AVNS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston Scientific (BSX - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, currently sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.